PROSHARES TRUST (ZBIO) Equity Average: 2023-2025
Historic Equity Average for Zenas BioPharma (ZBIO) over the last 2 years, with Sep 2025 value amounting to $218.0 million.
- Zenas BioPharma's Equity Average rose 517.18% to $218.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $218.0 million, marking a year-over-year increase of 517.18%. This contributed to the annual value of $43.4 million for FY2024, which is N/A change from last year.
- Per Zenas BioPharma's latest filing, its Equity Average stood at $218.0 million for Q3 2025, which was down 16.77% from $262.0 million recorded in Q2 2025.
- In the past 5 years, Zenas BioPharma's Equity Average ranged from a high of $335.9 million in Q4 2024 and a low of -$270.6 million during Q2 2024.
- Its 3-year average for Equity Average is $53.2 million, with a median of $126.7 million in 2024.
- Data for Zenas BioPharma's Equity Average shows a peak YoY spiked of 517.18% (in 2025) over the last 5 years.
- Zenas BioPharma's Equity Average (Quarterly) stood at -$214.0 million in 2023, then skyrocketed by 257.00% to $335.9 million in 2024, then surged by 517.18% to $218.0 million in 2025.
- Its last three reported values are $218.0 million in Q3 2025, $262.0 million for Q2 2025, and $298.4 million during Q1 2025.